206 related articles for article (PubMed ID: 28507496)
1. Safety and efficacy of venom immunotherapy: a real life study.
Kołaczek A; Skorupa D; Antczak-Marczak M; Kuna P; Kupczyk M
Postepy Dermatol Alergol; 2017 Apr; 34(2):159-167. PubMed ID: 28507496
[TBL] [Abstract][Full Text] [Related]
2. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
3. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
4. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
5. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and biologicals for the treatment of allergy to Hymenoptera stings.
Ridolo E; Pellicelli I; Kihlgren P; Nizi MC; Pucciarini F; Senna G; Incorvaia C
Expert Opin Biol Ther; 2019 Sep; 19(9):919-925. PubMed ID: 31190572
[No Abstract] [Full Text] [Related]
7. Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy.
Rostaher A; Fischer NM; Vigani A; Steblaj B; Martini F; Brem S; Favrot C; Kosnik M
Animals (Basel); 2023 Sep; 13(19):. PubMed ID: 37835609
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
Müller U; Helbling A; Berchtold E
J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
[TBL] [Abstract][Full Text] [Related]
9. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
10. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.
Ewan PW; Deighton J; Wilson AB; Lachmann PJ
Clin Exp Allergy; 1993 Aug; 23(8):647-60. PubMed ID: 8221268
[TBL] [Abstract][Full Text] [Related]
11. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
12. Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients.
Rosiek-Biegus M; Pawłowicz R; Kopeć A; Kosińska M; Wrześniak M; Nittner-Marszalska M
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35330002
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
14. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
15. Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects.
Arzt L; Bokanovic D; Schrautzer C; Laipold K; Möbs C; Pfützner W; Herzog SA; Vollmann J; Reider N; Bohle B; Aberer W; Sturm GJ
Allergy; 2018 Jun; 73(6):1223-1231. PubMed ID: 29171032
[TBL] [Abstract][Full Text] [Related]
16. Continuous immunotherapy for hymenoptera venom allergy using six month intervals.
Baenkler HW; Meusser-Storm S; Eger G
Allergol Immunopathol (Madr); 2005; 33(1):7-14. PubMed ID: 15777517
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy.
Severino M; Simioni L; Bonadonna P; Cantone R; Cortellini G; Crescioli S; D'Angelo A; La Rosa L; Macchia D; Martignago I; Massolo A; Reccardini F; Bagnasco D; Passalacqua G
World Allergy Organ J; 2019 Dec; 12(12):100086. PubMed ID: 31768218
[TBL] [Abstract][Full Text] [Related]
18. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
19. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
